Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 3

Completed

Conditions: Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
Childhood Acute Basophilic Leukemia
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Eosinophilic Leukemia
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myelomonocytic Leukemia (M4)
Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes

Interventions: Drug: asparaginase
Drug: daunorubicin hydrochloride
Drug: cytarabine
Drug: thioguanine
Drug: etoposide
Other: laboratory biomarker analysis

First Posted Date: 2006-08-29

Last Posted Date: 2022-01-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 205

Registration Number: NCT00369317

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Johns Hopkins University-Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 94 locations

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

First Posted Date: 2006-08-17

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00365755

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: etoposide
Drug: carboplatin

First Posted Date: 2006-08-15

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 908

Registration Number: NCT00363415

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye

Not Applicable

Conditions: Retinoblastoma

First Posted Date: 2006-08-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00360750

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 9 locations

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Lymphoma
Central Nervous System Tumor, Pediatric
Leukemia
Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide

First Posted Date: 2006-07-27

Last Posted Date: 2014-10-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00357500

Locations: 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 7 locations

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: vorinostat
Drug: cytarabine
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00357305

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

Phase 3

Completed

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Biological: filgrastim

First Posted Date: 2006-07-20

Last Posted Date: 2020-01-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 109

Registration Number: NCT00354744

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States

and more 162 locations

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Phase 1

Terminated

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Childhood Anaplastic Large Cell Lymphoma

Interventions: Biological: monoclonal antibody SGN-30
Drug: therapeutic hydrocortisone
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Drug: methotrexate
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-20

Last Posted Date: 2018-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00354107

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Adriamycin®
Drug: Vinblastine
Drug: Nitrogen Mustard
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Bleomycin
Drug: Etoposide
Drug: Prednisone
Biological: G-CSF
Procedure: Radiotherapy

First Posted Date: 2006-07-14

Last Posted Date: 2023-09-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 81

Registration Number: NCT00352027

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States

and more 3 locations

Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

First Posted Date: 2006-07-12

Last Posted Date: 2008-08-26

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 39

Registration Number: NCT00351195

Locations: 🇩🇰
Århus Sygehus, Dept. of Oncology, Århus, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy